Galmed keeps Nasdaq listing after bid-price fix
Galmed Pharmaceuticals has cured its Nasdaq minimum bid price deficiency, keeping its ordinary shares listed on The Nasdaq Stock Market.
Rhea-AI Filing Summary
Galmed Pharmaceuticals Ltd. (GLMD) reports that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company’s ordinary shares will continue to be listed and traded on The Nasdaq Stock Market after maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days.
Galmed had previously been notified on January 29, 2026 of a bid-price deficiency and went through an initial and an additional 180-day compliance period before achieving the required trading performance between August 20, 2026 and September 2, 2026. This matter is now closed, and the report is incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.
Positive
- Galmed has regained compliance with Nasdaq Listing Rule 5550(a)(2), ensuring its ordinary shares remain listed and traded on The Nasdaq Stock Market.
Negative
- None.
Key Figures
Minimum bid price threshold: $1.00 per share
Consecutive trading days at or above threshold: 10 trading days
Initial compliance period length: 180 calendar days
+3 more
6 metrics
Minimum bid price threshold
$1.00 per share
Required closing bid price under Nasdaq Listing Rule 5550(a)(2)
Consecutive trading days at or above threshold
10 trading days
From August 20, 2026 through September 2, 2026, used to regain compliance
Initial compliance period length
180 calendar days
First deadline to regain minimum bid price compliance, ending July 28, 2026
Additional compliance period length
180 calendar days
Second period granted after the initial 180-day period expired without compliance
Deficiency notice date
January 29, 2026
Date Nasdaq notified Galmed of failure to maintain $1.00 bid price for 30 days
Compliance confirmation date
September 3, 2026
Date Nasdaq staff notified Galmed it had regained bid price compliance
Key Terms
minimum bid price requirement, Nasdaq Listing Rule 5550(a)(2), Form 6-K, Registration Statements on Form S-8, +1 more
5 terms
minimum bid price requirement market
"regained compliance with the minimum bid price requirement set forth"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
Form 6-K regulatory
"This Form 6-K is incorporated by reference into the Company’s Registration Statements"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Registration Statements on Form S-8 regulatory
"incorporated by reference into the Company’s Registration Statements on Form S-8"
Registration Statement on Form F-3 regulatory
"and the Company’s Registration Statement on Form F-3"
A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.
FAQ
What did Galmed Pharmaceuticals (GLMD) announce regarding its Nasdaq listing?
Galmed announced it has regained compliance with the Nasdaq minimum bid price requirement under Rule 5550(a)(2), and its ordinary shares will continue to be listed and traded on The Nasdaq Stock Market after resolving the prior deficiency.
How did GLMD regain compliance with Nasdaq’s minimum bid price rule?
Galmed regained compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days from August 20, 2026 through September 2, 2026, satisfying Nasdaq Listing Rule 5550(a)(2).
When was Galmed (GLMD) first notified of its Nasdaq bid price deficiency?
Galmed was notified on January 29, 2026 that it had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days, triggering the Nasdaq Listing Rule 5550(a)(2) deficiency process.
How long was the compliance period given to GLMD to fix the bid price issue?
Galmed was initially given a 180-calendar-day compliance period until July 28, 2026, and after not regaining compliance in that period, received an additional 180-calendar-day compliance period to cure the deficiency.
How does this 6-K for GLMD relate to its existing registration statements?
This report is incorporated by reference into Galmed’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and Form F-3 (Nos. 333-272722, 333-283241), updating those offerings with the Nasdaq compliance development.
AI-generated analysis. How Rhea-AI works. Not financial advice.
